Supernus Pharmaceuticals Affirms FY2026 Sales Guidance of $840.000M-$870.000M vs $862.242M Est

Benzinga Newsdesk www.benzinga.com Negative 48.6%

Neg 48.6% Neu 0% Pos 0%

Comments

No comments yet. Be the first!